000163594 001__ 163594
000163594 005__ 20230915090526.0
000163594 0247_ $$2pmid$$apmid:35207351
000163594 0247_ $$2doi$$a10.3390/jcm11041074
000163594 0247_ $$2altmetric$$aaltmetric:123289614
000163594 0247_ $$2pmc$$apmc:PMC8875136
000163594 037__ $$aDZNE-2022-00340
000163594 082__ $$a610
000163594 1001_ $$aBendig, Jonas$$b0
000163594 245__ $$aFeasibility of a Multimodal Telemedical Intervention for Patients with Parkinson’s Disease—A Pilot Study
000163594 260__ $$aBasel$$bMDPI$$c2022
000163594 3367_ $$2DRIVER$$aarticle
000163594 3367_ $$2DataCite$$aOutput Types/Journal article
000163594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1649758310_19478
000163594 3367_ $$2BibTeX$$aARTICLE
000163594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163594 3367_ $$00$$2EndNote$$aJournal Article
000163594 520__ $$aSymptoms of Parkinson's disease (PD) can be controlled well, but treatment often requires expert judgment. Telemedicine and sensor-based assessments can allow physicians to better observe the evolvement of symptoms over time, in particular with motor fluctuations. In addition, they potentially allow less frequent visits to the expert's office and facilitate care in rural areas. A variety of systems with different strengths and shortcomings has been investigated in recent years. We designed a multimodal telehealth intervention (TelePark) to mitigate the shortcomings of individual systems and assessed the feasibility of our approach in 12 patients with PD over 12 weeks in preparation for a larger randomized controlled trial. TelePark uses video visits, a smartphone app, a camera system, and wearable sensors. Structured training included setting up the equipment in patients' homes and group-based online training. Usability was assessed by questionnaires and semi-standardized telephone interviews. Overall, 11 out of 12 patients completed the trial (5 female, 6 male). Mean age was 65 years, mean disease duration 7 years, mean MoCA score 27. Adherence was stable throughout the study and 79% for a short questionnaire administered every second day, 62% for medication confirmation, and 33% for an electronic Hauser diary. Quality of life did not change in the course of the study, and a larger cohort will be required to determine the effect on motor symptoms. Interviews with trial participants identified motivations to use such systems and areas for improvements. These insights can be helpful in designing similar trials.
000163594 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163594 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000163594 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000163594 7001_ $$0P:(DE-2719)2630412$$aWolf, Hanna$$b1$$udzne
000163594 7001_ $$aMark, Tony$$b2
000163594 7001_ $$0P:(DE-2719)9001473$$aFrank, Anika$$b3$$udzne
000163594 7001_ $$aMathiebe, Josephine$$b4
000163594 7001_ $$aScheibe, Madlen$$b5
000163594 7001_ $$aMüller, Gabriele$$b6
000163594 7001_ $$0P:(DE-2719)9000775$$aStahr, Marcus$$b7$$udzne
000163594 7001_ $$00000-0003-0264-0960$$aSchmitt, Jochen$$b8
000163594 7001_ $$aReichmann, Heinz$$b9
000163594 7001_ $$aLoewenbrück, Kai F.$$b10
000163594 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn H.$$b11$$eLast author
000163594 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm11041074$$gVol. 11, no. 4, p. 1074 -$$n4$$p1074$$tJournal of Clinical Medicine$$v11$$x2077-0383$$y2022
000163594 8564_ $$uhttps://pub.dzne.de/record/163594/files/Bendig_2022_Journal%20of%20Clinical%20Medicine_1.pdf$$yOpenAccess
000163594 8564_ $$uhttps://pub.dzne.de/record/163594/files/Bendig_2022_Journal%20of%20Clinical%20Medicine_1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163594 909CO $$ooai:pub.dzne.de:163594$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163594 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2630412$$aExternal Institute$$b1$$kExtern
000163594 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001473$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000163594 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000775$$aExternal Institute$$b7$$kExtern
000163594 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000163594 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163594 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000163594 9141_ $$y2022
000163594 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000163594 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000163594 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000163594 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000163594 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163594 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000163594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2021$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-04T08:13:34Z
000163594 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-04T08:13:34Z
000163594 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-09-04T08:13:34Z
000163594 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-17
000163594 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000163594 920__ $$lyes
000163594 9201_ $$0I:(DE-2719)1710012$$kClinical Study Team Dresden ; AG Falkenburger$$lClinical Study Team Dresden$$x0
000163594 9201_ $$0I:(DE-2719)1710008$$kAG Donix$$lClinical planning and intersite group$$x1
000163594 9201_ $$0I:(DE-2719)1710001$$kAG Kempermann 1$$lAdult Neurogenesis$$x2
000163594 980__ $$ajournal
000163594 980__ $$aVDB
000163594 980__ $$aUNRESTRICTED
000163594 980__ $$aI:(DE-2719)1710012
000163594 980__ $$aI:(DE-2719)1710008
000163594 980__ $$aI:(DE-2719)1710001
000163594 9801_ $$aFullTexts